You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

378 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Updated
Dec 2025
Drug
Other Name(s): Xgeva®; Wyost™; Osenvelt™
Updated
Dec 2025
Drug
Other Name(s): Truqap™
Updated
Dec 2025
Drug
Other Name(s): Vitrakvi®
Updated
Dec 2025
Drug
Other Name(s): Elrexfio™
Updated
Dec 2025
Drug
Other Name(s): Rybrevant®
Updated
Dec 2025
Drug
Other Name(s): Vyloy®
Updated
Dec 2025
Drug
Other Name(s): Votrient®
Updated
Dec 2025
Guidelines and Advice
Status: Current
Version: 1
Updated
Nov 2025
Drug
Other Name(s): Opdivo®
Updated
Dec 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Updated
Dec 2025

Pages